Biography

Michael Hust studied biology at the Carl von Ossietzky Universität in Oldenburg, Germany, from 1993-1999. He received his PhD from the Leibniz Universität in Hannover, Germany, in 2002. Since end of 2002 he is working as group leader at the Technische Universität Braunschweig, Germany. In 2011, he finished his professorial dissertation (Habilitation, venia legendi for Biotechnology) and was appointed as Privatdozent (PD). In 2014 he was appointed as professor for biotechnology. Since 2022, he is head of the department of Medical Biotechnology.
He is working on the development of recombinant antibodies for diagnostics and therapy with a focus on infectious and toxins, e.g. therapeutic antibodies against Marburg virus, Ebola Sudan virus, Western equine encephalitis virus, SARS-CoV-2, botulinum toxins or diphtheria toxin. An other research topic are autoimmune diseases (e.g. IgA nephropathy or autoimmune encephalitis). He initiated the EU AntibotABE consortium and is very active in international research cooperations. Another field of work is the identification of biomarkers of pathogens using ORFeome phage display for diagnostics and vaccine development which also resulted in the BMBF GO-Bio8 funded tick vaccine project. He co-founded four biotech companies, the mAb-Factory GmbH in 2007, YUMAB GmbH (www.yumab.com) in 2012, Norden Vaccines GmbH in 2019 and CORAT Therapeutics 2020 (www.corat-therapeutics.com).